145 related articles for article (PubMed ID: 21316387)
1. Cognitive enhancers for the treatment of neuropsychiatric disorders: clinical and preclinical investigations.
Kantak KM; Hofmann SG
Pharmacol Biochem Behav; 2011 Aug; 99(2):113-5. PubMed ID: 21316387
[No Abstract] [Full Text] [Related]
2. Preclinical research into cognition enhancers.
Sarter M
Trends Pharmacol Sci; 2006 Nov; 27(11):602-8. PubMed ID: 16997388
[TBL] [Abstract][Full Text] [Related]
3. [Challenging pharmacotherapy in dementia].
Ihl R
MMW Fortschr Med; 2009 Mar; 151(13):46-8. PubMed ID: 19504818
[No Abstract] [Full Text] [Related]
4. Drugs influencing cognitive function.
Kuruvilla A; Devi V
Indian J Physiol Pharmacol; 1994 Oct; 38(4):241-51. PubMed ID: 7883287
[No Abstract] [Full Text] [Related]
5. Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes. Update 2014.
Froestl W; Muhs A; Pfeifer A
J Alzheimers Dis; 2014; 42(1):1-68. PubMed ID: 24903780
[TBL] [Abstract][Full Text] [Related]
6. Cognitive enhancement: promises and perils.
Hyman SE
Neuron; 2011 Feb; 69(4):595-8. PubMed ID: 21338872
[TBL] [Abstract][Full Text] [Related]
7. Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction.
Cincotta SL; Yorek MS; Moschak TM; Lewis SR; Rodefer JS
Curr Opin Investig Drugs; 2008 Jan; 9(1):47-56. PubMed ID: 18183531
[TBL] [Abstract][Full Text] [Related]
8. Putative cognitive enhancers in preclinical models related to schizophrenia: the search for an elusive target.
Barak S; Weiner I
Pharmacol Biochem Behav; 2011 Aug; 99(2):164-89. PubMed ID: 21420999
[TBL] [Abstract][Full Text] [Related]
9. Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art.
Fariello RG
Funct Neurol; 1997; 12(3-4):221-5. PubMed ID: 9218984
[No Abstract] [Full Text] [Related]
10. Drug targets for cognitive enhancement in neuropsychiatric disorders.
Wallace TL; Ballard TM; Pouzet B; Riedel WJ; Wettstein JG
Pharmacol Biochem Behav; 2011 Aug; 99(2):130-45. PubMed ID: 21463652
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical treatment of cognitive disorders in Alzheimer's disease.
Senin U; Cherubini A; Palumbo B; Mecocci P
Funct Neurol; 1997; 12(3-4):211-2. PubMed ID: 9218980
[No Abstract] [Full Text] [Related]
12. [The pharmacotherapy of the cognitive disorders in Alzheimer's disease. Guidelines for rational drug use--a review].
Strnad J; Bahro M
Dtsch Med Wochenschr; 2000 Jul; 125(27):835-9. PubMed ID: 10929539
[No Abstract] [Full Text] [Related]
13. Donepezil-induced nightmares in mild cognitive impairment.
Kitabayashi Y; Ueda H; Tsuchida H; Yamashita T; Narumoto J; Fukui K
Psychiatry Clin Neurosci; 2006 Feb; 60(1):123-4. PubMed ID: 16472374
[No Abstract] [Full Text] [Related]
14. Galantamine for Alzheimer's disease and mild cognitive impairment.
Cusi C; Cantisani TA; Celani MG; Incorvaia B; Righetti E; Candelise L;
Neuroepidemiology; 2007; 28(2):116-7. PubMed ID: 17409773
[No Abstract] [Full Text] [Related]
15. Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia.
Floresco SB; Geyer MA; Gold LH; Grace AA
Schizophr Bull; 2005 Oct; 31(4):888-94. PubMed ID: 16079387
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo efficacy in cognition models.
O'Donnell CJ; Rogers BN; Bronk BS; Bryce DK; Coe JW; Cook KK; Duplantier AJ; Evrard E; Hajós M; Hoffmann WE; Hurst RS; Maklad N; Mather RJ; McLean S; Nedza FM; O'Neill BT; Peng L; Qian W; Rottas MM; Sands SB; Schmidt AW; Shrikhande AV; Spracklin DK; Wong DF; Zhang A; Zhang L
J Med Chem; 2010 Feb; 53(3):1222-37. PubMed ID: 20043678
[TBL] [Abstract][Full Text] [Related]
17. Clinical inquiries. Does treatment with donepezil improve memory for patients with mild cognitive impairment?
Stiles MM; Martin S; Persons RK
J Fam Pract; 2006 May; 55(5):435-6. PubMed ID: 16670040
[No Abstract] [Full Text] [Related]
18. Cognitive enhancers: molecules, mechanisms and minds.
Frenguelli BG
Neuropharmacology; 2013 Jan; 64():1. PubMed ID: 22985720
[No Abstract] [Full Text] [Related]
19. Medications for Alzheimer's disease. Benefits of currently approved drugs are limited, but research continues.
Harv Ment Health Lett; 2011 Apr; 27(10):4-5. PubMed ID: 21786469
[No Abstract] [Full Text] [Related]
20. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets.
Terry AV; Buccafusco JJ; Wilson C
Behav Brain Res; 2008 Dec; 195(1):30-8. PubMed ID: 18241938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
